"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

7500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-22

Study Completion Date

2020-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of the ANRS 12332 HepNile study cohort is to assess in "Real-Life" condition the efficacy and the safety profile of new Direct Acting Antivirals (DAAs) introduced in the Egyptian National Treatment Programme for the treatment of Chronic Hepatitis C (CHC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the National Treatment Program of Hepatitis C in Egypt

NCT02101177

Chronic Hepatitis C

WITHDRAWN

Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)

NCT01276756

Chronic Hepatitis c

COMPLETED PHASE2/PHASE3

Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients

NCT01197157

Hepatitis C

COMPLETED PHASE2/PHASE3

Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse

NCT04662138

Hepatitis C Relapse Antivirals

UNKNOWN

Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)

NCT00158522

Hepatitis C

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clinical trials are performed under optimal conditions where patients are highly selected with no co-morbidity, clinical supervision is provided by the best specialists in the field, and strict protocols are used to enhance patients' compliance. Thus, results may not be generalizable to real-world clinical practice.

Observational studies are now gaining attention, showing with previous treatments (combined pegylated interferon and ribavirin) a wide range of results in terms of treatment effectiveness (SVR from 21% to 63% overall), whereas related pivotal clinical trials had estimated SVRs between 54% and 63% overall.

Egypt is the first low/middle-income country where a national treatment program has been established on a large scale, allowing an evaluation that might be useful to itself and other similar countries. A real life evaluation will be particularly relevant now that new anti-viral drugs, direct-acting antivirals, are being introduced in Egypt.

ANRS 12332 HepNile cohort study will allow "in real life condition" the study of:

* Efficacy (cure rate) and safety of new HCV regimens introduced in Egypt
* Emergence of resistance variants for patients with virological breakthrough
* Factors associated with treatment failure
* Drug-Drug interactions
* Adherence to the treatment regimens

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HCV RNA positivity
* 18 years =\< Age =\< 70 years
* Patients \>= 65 years should undergo cardiological assessment prior to therapy by ECG echocardiography and cardiological consultation
* Effective contraception (Women of childbearing potential should use an effective contraception; Male patients and their female partners must also practice effective contraception) both during treatment and for the 3-months post-therapy); no breast-feeding
* Signed informed consent and willingness to participate in the study

Exclusion Criteria

* Child C cirrhotic patients
* Platelet count \> 50000/mm3
* Hepatocellular Carcinoma (HCC), except 6 months after intervention aiming at cure with no evidence of activity by dynamic imaging (CT or MRI)
* Extra-hepatic malignancy except after two years of disease-free interval (in case of lymphomas and chronic lymphatic leukemia, treatment can be initiated immediately after remission)
* Pregnancy or inability to use effective contraception
* inadequately controlled diabetes mellitus (HbA1C\>9%)

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No